Teknova Q1 revenue up 5% to $9.8M, net loss narrows to $4.6M, guidance reaffirmed

Alpha Teknova, Inc.

2025-Q1 EPS reported -$0.09 revenue$9,795,000

Q1 total revenue $9.8M (+5% YoY); Lab Essentials $8.1M (+12%), Clinical Solutions $1.2M (-32%).
Net loss narrowed to $4.6M ($0.09/share) from $8.1M ($0.20/share) in Q1 2024.
Adjusted EBITDA loss improved to $2.5M from $3.8M; free cash outflow decreased to $4.3M from $6.7M.
Exclusive collaboration with Pluristyx to manufacture/distribute PluriFreeze cryopreservation system in US/Canada.
Reaffirms FY2025 revenue guidance of $39-42M and free cash outflow under $12M.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-067005
form_type: 8-K
ticker: TKNO
cik: 0001850902
company_name: Alpha Teknova, Inc.
filed_at: 2025-05-08T23:59:59+00:00
discovered_at: 2026-05-14T18:02:50.149963+00:00
generated_at: 2026-05-22T05:30:45.125320+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-067005
json_url: https://secwatch.observer/filing/0000950170-25-067005.json
markdown_url: https://secwatch.observer/filing/0000950170-25-067005.md
text_url: https://secwatch.observer/filing/0000950170-25-067005.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1850902/000095017025067005/0000950170-25-067005-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1850902/000095017025067005/tkno-20250508.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-067005

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.